These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 31314790)
1. Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome. Roubicek T; Stros J; Kucera P; Nedbal P; Cerny J; Polasek R; Wichterle D PLoS One; 2019; 14(7):e0219966. PubMed ID: 31314790 [TBL] [Abstract][Full Text] [Related]
2. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients. Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830 [TBL] [Abstract][Full Text] [Related]
3. Local electrogram delay recorded from left ventricular lead at implant predicts response to cardiac resynchronization therapy: retrospective study with 1 year follow up. Polasek R; Kucera P; Nedbal P; Roubicek T; Belza T; Hanuliakova J; Horak D; Wichterle D; Kautzner J BMC Cardiovasc Disord; 2012 May; 12():34. PubMed ID: 22607487 [TBL] [Abstract][Full Text] [Related]
4. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. Yu CM; Fung JW; Zhang Q; Chan CK; Chan I; Chan YS; Kong SL; Sanderson JE; Lam CW J Card Fail; 2005 Jun; 11(5 Suppl):S42-6. PubMed ID: 15948100 [TBL] [Abstract][Full Text] [Related]
5. Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response? Tawfik Ghanem M; Allam LE; Samir Ahmed R Indian Heart J; 2019; 71(3):229-234. PubMed ID: 31543195 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population. Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557 [TBL] [Abstract][Full Text] [Related]
7. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable? Hoogslag GE; Höke U; Thijssen J; Auger D; Marsan NA; Wolterbeek R; Holman ER; Schalij MJ; Bax JJ; Verwey HF; Delgado V Pacing Clin Electrophysiol; 2013 Nov; 36(11):1391-401. PubMed ID: 23826659 [TBL] [Abstract][Full Text] [Related]
8. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288 [TBL] [Abstract][Full Text] [Related]
9. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study. Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191 [TBL] [Abstract][Full Text] [Related]
10. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864 [TBL] [Abstract][Full Text] [Related]
11. Clinical and classic echocardiographic features of patients with, and without, left ventricle reverse remodeling following the introduction of cardiac resynchronization therapy. Wiliński J; Czarnecka D; Wojciechowska W; Kloch-Badełek M; Jastrzębski M; Bacior B; Sondej T; Kusak P; Przybyła A; Kawecka-Jaszcz K Cardiol J; 2011; 18(2):157-64. PubMed ID: 21432822 [TBL] [Abstract][Full Text] [Related]
12. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Linde C; Gold MR; Abraham WT; St John Sutton M; Ghio S; Cerkvenik J; Daubert C; Eur Heart J; 2013 Sep; 34(33):2592-9. PubMed ID: 23641006 [TBL] [Abstract][Full Text] [Related]
13. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Gold MR; Daubert C; Abraham WT; Ghio S; St John Sutton M; Hudnall JH; Cerkvenik J; Linde C Heart Rhythm; 2015 Mar; 12(3):524-530. PubMed ID: 25460860 [TBL] [Abstract][Full Text] [Related]
14. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. Stanciu AE; Vatasescu RG; Stanciu MM; Iorgulescu C; Vasile AI; Dorobantu M Clin Biochem; 2013 Feb; 46(3):230-4. PubMed ID: 23159290 [TBL] [Abstract][Full Text] [Related]
15. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. Vanderheyden M; Mullens W; Delrue L; Goethals M; de Bruyne B; Wijns W; Geelen P; Verstreken S; Wellens F; Bartunek J J Am Coll Cardiol; 2008 Jan; 51(2):129-36. PubMed ID: 18191736 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. Linde C; Abraham WT; Gold MR; St John Sutton M; Ghio S; Daubert C; J Am Coll Cardiol; 2008 Dec; 52(23):1834-1843. PubMed ID: 19038680 [TBL] [Abstract][Full Text] [Related]
17. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial. St John Sutton M; Linde C; Gold MR; Abraham WT; Ghio S; Cerkvenik J; Daubert JC; JACC Heart Fail; 2017 Mar; 5(3):169-178. PubMed ID: 28254122 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of biventricular pacing on preventing heart failure in patients with high degree atrioventricular block (BIVPACE-AVB Trial)]. Zhang XY; Shan QJ; Su YG; Yan J; Bao ZH; Gu X; Qiu JP; Qin SM; Xu J; Su H; Zhu H; Guo JF; Lu JP; Zou JG; Chen ML; Xu D; Cao KJ Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):331-7. PubMed ID: 27112612 [TBL] [Abstract][Full Text] [Related]
19. Echocardiography-based qualification and response assessment to cardiac resynchronisation therapy in patients with chronic heart failure. The matrix metalloproteinase-9 substudy. Szulik M; Stabryła-Deska J; Boidol J; Lenarczyk R; Kalarus Z; Kukulski T Kardiol Pol; 2011; 69(10):1043-51. PubMed ID: 22006606 [TBL] [Abstract][Full Text] [Related]
20. Presence of extensive LV remodeling limits the benefits of CRT in patients with intraventricular dyssynchrony. Carluccio E; Biagioli P; Alunni G; Murrone A; Pantano P; Biscottini E; Zuchi C; Zingarini G; Cavallini C; Ambrosio G JACC Cardiovasc Imaging; 2011 Oct; 4(10):1067-76. PubMed ID: 21999865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]